|
1
|
Savona M and Talpaz M: Chronic myeloid
leukemia: changing the treatment paradigms. Oncology (Williston
Park). 20:707–711; discussion 712–704, 719, 724. 2006.
|
|
2
|
Huang X, Cortes J and Kantarjian H:
Estimations of the increasing prevalence and plateau prevalence of
chronic myeloid leukemia in the era of tyrosine kinase inhibitor
therapy. Cancer. 118:3123–3127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kurzrock R, Gutterman JU and Talpaz M: The
molecular genetics of Philadelphia chromosome-positive leukemias. N
Engl J Med. 319:990–998. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tomoda K, Kato JY, Tatsumi E, Takahashi T,
Matsuo Y and Yoneda-Kato N: The Jab1/COP9 signalosome subcomplex is
a downstream mediator of Bcr-Abl kinase activity and facilitates
cell-cycle progression. Blood. 105:775–783. 2005. View Article : Google Scholar
|
|
5
|
Druker BJ, Talpaz M, Resta DJ, Peng B,
Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R,
Ohno-Jones S, et al: Efficacy and safety of a specific inhibitor of
the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J
Med. 344:1031–1037. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Druker BJ, Guilhot F, O’Brien SG, Gathmann
I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM,
Stone RM, et al; IRIS Investigators. Five-year follow-up of
patients receiving imatinib for chronic myeloid leukemia. N Engl J
Med. 355:2408–2417. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shah NP, Nicoll JM, Nagar B, Gorre ME,
Paquette RL, Kuriyan J and Sawyers CL: Multiple BCR-ABL kinase
domain mutations confer polyclonal resistance to the tyrosine
kinase inhibitor imatinib (STI571) in chronic phase and blast
crisis chronic myeloid leukemia. Cancer Cell. 2:117–125. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gorre ME, Mohammed M, Ellwood K, Hsu N,
Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571
cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 293:876–880. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Achkar W, Wafa A, Moassass F, Klein E
and Liehr T: Multiple copies of BCR-ABL fusion gene on two
isodicentric Philadelphia chromosomes in an imatinib
mesylate-resistant chronic myeloid leukemia patient. Oncol Lett.
5:1579–1582. 2013.PubMed/NCBI
|
|
10
|
Hochhaus A, Kreil S, Corbin AS, La Rosée
P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U,
et al: Molecular and chromosomal mechanisms of resistance to
imatinib (STI571) therapy. Leukemia. 16:2190–2196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O’Hare T, Walters DK, Stoffregen EP, Jia
T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC,
Deininger MW, et al: In vitro activity of Bcr-Abl inhibitors AMN107
and BMS-354825 against clinically relevant imatinib-resistant Abl
kinase domain mutants. Cancer Res. 65:4500–4505. 2005. View Article : Google Scholar
|
|
12
|
Martinelli G, Iacobucci I, Soverini S,
Palandri F, Castagnetti F, Rosti G and Baccarani M: Nilotinib: A
novel encouraging therapeutic option for chronic myeloid leukemia
patients with imatinib resistance or intolerance. Biologics.
1:121–127. 2007.PubMed/NCBI
|
|
13
|
Shah NP, Tran C, Lee FY, Chen P, Norris D
and Sawyers CL: Overriding imatinib resistance with a novel ABL
kinase inhibitor. Science. 305:399–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goh SS, Woodman OL, Pepe S, Cao AH, Qin C
and Ritchie RH: The red wine antioxidant resveratrol prevents
cardiomyocyte injury following ischemia-reperfusion via multiple
sites and mechanisms. Antioxid Redox Signal. 9:101–113. 2007.
View Article : Google Scholar
|
|
15
|
Winkelmann I, Diehl D, Oesterle D, Daniel
H and Wenzel U: The suppression of aberrant crypt multiplicity in
colonic tissue of 1,2-dimethylhydrazine-treated C57BL/6J mice by
dietary flavone is associated with an increased expression of Krebs
cycle enzymes. Carcinogenesis. 28:1446–1454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lafon CW: Stand dynamics of a
yellow-poplar (Liriodendron tulipifera L.) forest in the
Appalachian Mountains, Virginia, USA. Dendrochronologia. 22:43–52.
2004. View Article : Google Scholar
|
|
17
|
Rafinesque CS: Medical Flora or Manual of
the Medical Botany of the United States of North America. In two
volumes. Philadelphia: 1828
|
|
18
|
Graziose R, Rathinasabapathy T, Lategan C,
Poulev A, Smith PJ, Grace M, Lila MA and Raskin I: Antiplasmodial
activity of aporphine alkaloids and sesquiterpene lactones from
Liriodendron tulipifera L. J Ethnopharmacol. 133:26–30. 2011.
View Article : Google Scholar
|
|
19
|
Li WJ, Lin YC, Wu PF, Wen ZH, Liu PL, Chen
CY and Wang HM: Biofunctional constituents from Liriodendron
tulipifera with antioxidants and anti-melanogenic properties. Int J
Mol Sci. 14:1698–1712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Doskotch RW and el-Feraly FS: Antitumor
agents. II Tulipinolide, a new germacranolide sesquiterpene, and
constunolide Two cytotoxic substances from Liriodendron tulipifera
L. J Pharm Sci. 58:877–880. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moon MK, Oh HM, Kwon BM, Baek NI, Kim SH,
Kim JS and Kim DK: Farnesyl protein transferase and tumor cell
growth inhibitory activities of lipiferolide isolated from
Liriodendron tulipifera. Arch Pharm Res. 30:299–302. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Neelakantan S, Nasim S, Guzman ML, Jordan
CT and Crooks PA: Aminoparthenolides as novel anti-leukemic agents:
Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem
Lett. 19:4346–4349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaufmann SH and Hengartner MO: Programmed
cell death: Alive and well in the new millennium. Trends Cell Biol.
11:526–534. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kinghorn AD, Chin YW and Swanson SM:
Discovery of natural product anticancer agents from biodiverse
organisms. Curr Opin Drug Discov Devel. 12:189–196. 2009.PubMed/NCBI
|
|
25
|
Balunas MJ, Su B, Landini S, Brueggemeier
RW and Kinghorn AD: Interference by naturally occurring fatty acids
in a noncellular enzyme-based aromatase bioassay. J Nat Prod.
69:700–703. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao J: Nutraceuticals, nutritional
therapy, phytonutrients, and phytotherapy for improvement of human
health: A perspective on plant biotechnology application. Recent
Pat Biotechnol. 1:75–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong SW, Jung KH, Lee HS, Choi MJ, Son MK,
Zheng HM and Hong SS: SB365 inhibits angiogenesis and induces
apoptosis of hepatocellular carcinoma through modulation of
PI3K/Akt/mTOR signaling pathway. Cancer Sci. 103:1929–1937. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Oliveira LZ, Farias IL, Rigo ML,
Glanzner WG, Gonçalves PB, Cadoná FC, Cruz IB, Farias JG, Duarte
MM, Franco L, et al: Effect of Uncaria tomentosa extract on
apoptosis triggered by oxaliplatin exposure on HT29 cells. Evid
Based Complement Alternat Med. 2014:2747862014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deininger M, Buchdunger E and Druker BJ:
The development of imatinib as a therapeutic agent for chronic
myeloid leukemia. Blood. 105:2640–2653. 2005. View Article : Google Scholar
|
|
30
|
O’Hare T, Corbin AS and Druker BJ:
Targeted CML therapy: Controlling drug resistance, seeking cure.
Curr Opin Genet Dev. 16:92–99. 2006. View Article : Google Scholar
|
|
31
|
Jabbour E, Cortes J and Kantarjian H:
Nilotinib for the treatment of chronic myeloid leukemia: An
evidence-based review. Core Evid. 4:207–213. 2009. View Article : Google Scholar
|
|
32
|
Quintás-Cardama A, Kantarjian H and Cortes
J: Flying under the radar: The new wave of BCR-ABL inhibitors. Nat
Rev Drug Discov. 6:834–848. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Steelman LS, Pohnert SC, Shelton JG,
Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT, Raf/MEK/ERK,
PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.
Leukemia. 18:189–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kirchner D, Duyster J, Ottmann O, Schmid
RM, Bergmann L and Munzert G: Mechanisms of Bcr-Abl-mediated
NF-kappaB/Rel activation. Exp Hematol. 31:504–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Klejman A, Schreiner SJ,
Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE and
Skorski T: The Src family kinase Hck couples BCR/ABL to STAT5
activation in myeloid leukemia cells. EMBO J. 21:5766–5774. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hemmeryckx B, van Wijk A, Reichert A,
Kaartinen V, de Jong R, Pattengale PK, Gonzalez-Gomez I, Groffen J
and Heisterkamp N: Crkl enhances leukemogenesis in BCR/ABL P190
transgenic mice. Cancer Res. 61:1398–1405. 2001.PubMed/NCBI
|
|
37
|
Hoelbl A, Schuster C, Kovacic B, Zhu B,
Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et
al: Stat5 is indispensable for the maintenance of bcr/abl-positive
leukaemia. EMBO Mol Med. 2:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cabot MC, Giuliano AE, Han TY and Liu YY:
SDZ PSC 833, the cyclosporine A analogue and multidrug resistance
modulator, activates ceramide synthesis and increases vinblastine
sensitivity in drug-sensitive and drug-resistant cancer cells.
Cancer Res. 59:880–885. 1999.PubMed/NCBI
|
|
39
|
Selzner M, Bielawska A, Morse MA, Rüdiger
HA, Sindram D, Hannun YA and Clavien PA: Induction of apoptotic
cell death and prevention of tumor growth by ceramide analogues in
meta-static human colon cancer. Cancer Res. 61:1233–1240.
2001.PubMed/NCBI
|
|
40
|
Bedi A, Zehnbauer BA, Barber JP, Sharkis
SJ and Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic
myeloid leukemia. Blood. 83:2038–2044. 1994.PubMed/NCBI
|
|
41
|
Deming PB, Schafer ZT, Tashker JS, Potts
MB, Deshmukh M and Kornbluth S: Bcr-Abl-mediated protection from
apoptosis downstream of mitochondrial cytochrome c release. Mol
Cell Biol. 24:10289–10299. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bueno-da-Silva AE, Brumatti G, Russo FO,
Green DR and Amarante-Mendes GP: Bcr-Abl-mediated resistance to
apoptosis is independent of constant tyrosine-kinase activity. Cell
Death Differ. 10:592–598. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Altieri DC: Survivin and IAP proteins in
cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kreuger MR, Grootjans S, Biavatti MW,
Vandenabeele P and D’Herde K: Sesquiterpene lactones as drugs with
multiple targets in cancer treatment: Focus on parthenolide.
Anticancer Drugs. 23:883–896. 2012.PubMed/NCBI
|
|
45
|
Saikali M, Ghantous A, Halawi R, Talhouk
SN, Saliba NA and Darwiche N: Sesquiterpene lactones isolated from
indigenous Middle Eastern plants inhibit tumor promoter-induced
transformation of JB6 cells. BMC Complement Altern Med. 12:892012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Viennois E, Xiao B, Ayyadurai S, Wang L,
Wang PG, Zhang Q, Chen Y and Merlin D: Micheliolide, a new
sesquiterpene lactone that inhibits intestinal inflammation and
colitis-associated cancer. Lab Invest. 94:950–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yeh CT, Huang WC, Rao YK, Ye M, Lee WH,
Wang LS, Tzeng DT, Wu CH, Shieh YS, Huang CY, et al: A
sesquiterpene lactone antrocin from Antrodia camphorata negatively
modulates JAK2/STAT3 signaling via microRNA let-7c and induces
apoptosis in lung cancer cells. Carcinogenesis. 34:2918–2928. 2013.
View Article : Google Scholar : PubMed/NCBI
|
